Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $14.00 Average Price Target from Brokerages

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $14.00.

Several analysts have commented on KLRS shares. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. Wall Street Zen downgraded Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Chardan Capital initiated coverage on Kalaris Therapeutics in a research note on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price target for the company.

Insider Activity

In other news, Director Srinivas Akkaraju acquired 479,847 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were acquired at an average cost of $10.42 per share, with a total value of $5,000,005.74. Following the acquisition, the director directly owned 1,979,847 shares of the company’s stock, valued at approximately $20,630,005.74. The trade was a 31.99% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 74.99% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kalaris Therapeutics

Several large investors have recently bought and sold shares of KLRS. RTW Investments LP purchased a new stake in Kalaris Therapeutics during the fourth quarter valued at $10,972,000. Paradigm Biocapital Advisors LP purchased a new position in shares of Kalaris Therapeutics in the 4th quarter worth $5,908,000. Siren L.L.C. grew its stake in shares of Kalaris Therapeutics by 36.9% in the 4th quarter. Siren L.L.C. now owns 435,798 shares of the company’s stock worth $3,678,000 after buying an additional 117,534 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Kalaris Therapeutics in the 4th quarter worth about $3,402,000. Finally, Ikarian Capital LLC purchased a new stake in shares of Kalaris Therapeutics during the 4th quarter valued at about $3,038,000. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Stock Performance

Shares of NASDAQ:KLRS opened at $9.96 on Friday. The firm has a fifty day moving average price of $9.41 and a 200 day moving average price of $7.08. Kalaris Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $12.90. The firm has a market cap of $186.25 million, a price-to-earnings ratio of -2.64 and a beta of -0.13.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.